# An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct04443088/  
OnCo record `nct04443088` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of INV-1120 run by Shenzhen Ionova Life Sciences Co., Ltd., now recruiting.

## Summary

An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors is a phase 1 interventional study registered as NCT04443088 by Shenzhen Ionova Life Sciences Co., Ltd., with 78 participants planned, started 2020-06-26. Conditions recorded: Cancer, Solid Tumor, Adult, Cancer Metastatic, Solid Carcinoma, Solid Tumor, Unspecified, Adult and Tumor, Solid. Interventions recorded: INV-1120 and Pembrolizumab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04443088
- Phase: 1
- Setting: A Phase 1a/1b, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Evidence of Antitumor Activity of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors
- Sponsor: Shenzhen Ionova Life Sciences Co., Ltd.
- Enrolled: 78

## Sources

- ClinicalTrials.gov NCT04443088: https://clinicaltrials.gov/study/NCT04443088

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [INV-1120](https://onco.cc/drugs/inv-1120/)
- companies: [Shenzhen Ionova Life Sciences](https://onco.cc/companies/shenzhen-ionova-life-sciences/)

---
JSON: https://onco.cc/api/v1/entities/nct04443088.json